Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial

Résumé fourni par la source

Corrigendum on: Abdellatif A, Zhao L, Obermeyer K, Vranic Z, Marder BA and Scandling JD (2025) Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial. Front. Immunol. 16:1516146. doi: 10.3389/fimmu.2025.1516146In the published article, the reference for [The high impact of gout on lowering patient QOL is well established, and these effects are more pronounced in KT recipients] was incorrectly written as [40]. It should be [27].The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.